Literature DB >> 22638889

Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion.

Konstantinos Karatolios1, Sabine Pankuweit, Bernhard Maisch.   

Abstract

The aim of this study was to examine the biochemical composition of pericardial effusions of different etiology and to evaluate the diagnostic utility of biochemical parameters and tumor markers to discriminate malignant from benign effusion. Pericardial and serum levels of biochemical parameters and tumor markers were compared in 105 patients who underwent pericardiocentesis and pericardioscopy with targeted epicardial biopsy. Etiologic diagnosis was based on pericardial fluid and epicardial biopsy analysis by cytology, histology, immunohistochemistry, microbiology and polymerase chain reaction. The total of 105 patients comprised 29 patients with malignant and 76 patients with non-malignant pericardial effusions (40 autoreactive, 28 viral, 5 postcardiotomy syndromes and 3 associated with systemic diseases). Malignant pericardial effusions had significantly higher pericardial fluid levels of the tumor markers CEA, CA 19-9, CA 72-4, SCC and NSE (p < 0.001, p = 0.002, p < 0.001, p = 0.004 and p < 0.001, respectively) as well as higher pericardial fluid hemoglobin (p < 0.001), pericardial fluid white blood cells (p = 0.003), pericardial fluid LDH (p < 0.001) and ratio of pericardial to serum LDH levels compared to benign effusions. None of the biochemical or cell-count parameters tested proved to be accurate enough for distinguishing malignant from benign effusions. However, measurement of pericardial CA 72-4 levels offered a high diagnostic accuracy for malignancy, particularly in bloody pericardial effusions. None of the biochemical parameters tested was useful for the discrimination of malignant from benign effusions. However, measurement of pericardial CA 72-4 levels in bloody pericardial effusions yielded a high diagnostic accuracy and thus offers the potential as a diagnostic tool to distinguish between malignant and benign effusions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22638889     DOI: 10.1007/s10741-012-9327-x

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  35 in total

1.  Intrapericardial treatment of autoreactive myocarditis with triamcinolon. Successful administration in patients with minimal pericardial effusion.

Authors:  B Maisch; A D Ristić; P M Seferovic; D H Spodick
Journal:  Herz       Date:  2000-12       Impact factor: 1.443

2.  The usefulness of diagnostic tests on pericardial fluid.

Authors:  D G Meyers; R E Meyers; T W Prendergast
Journal:  Chest       Date:  1997-05       Impact factor: 9.410

3.  Pericardoscopy for primary management of pericardial effusion in cancer patients.

Authors:  H L Porte; T J Janecki-Delebecq; L Finzi; D G Métois; A Millaire; A J Wurtz
Journal:  Eur J Cardiothorac Surg       Date:  1999-09       Impact factor: 4.191

4.  Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer.

Authors:  O C Burghuber; B Worofka; G Schernthaner; N Vetter; M Neumann; R Dudczak; R Kuzmits
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

5.  Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.

Authors:  J S Gronowitz; R Bergström; E Nôu; S Påhlman; O Brodin; S Nilsson; C F Källander
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

Review 6.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

7.  Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.

Authors:  Johanna Louhimo; Henrik Alfthan; Ulf-Håkan Stenman; Caj Haglund
Journal:  Oncology       Date:  2004       Impact factor: 2.935

Review 8.  [New possibilities of diagnostics and therapy of pericarditis].

Authors:  B Maisch; K Karatolios
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

Review 9.  Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections.

Authors:  P Gold; J Shuster; S O Freedman
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

10.  Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma.

Authors:  H Kato; T Torigoe
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

View more
  15 in total

Review 1.  Immortalization protocols used in cell culture models of human breast morphogenesis.

Authors:  T Gudjonsson; R Villadsen; L Rønnov-Jessen; O W Petersen
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

2.  The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion.

Authors:  M Szturmowicz; A Pawlak-Cieślik; A Fijałkowska; J Gątarek; A Skoczylas; M Dybowska; K Błasińska-Przerwa; R Langfort; W Tomkowski
Journal:  Support Care Cancer       Date:  2017-03-03       Impact factor: 3.603

3.  [Diagnostics and therapy of pericarditis and pericardial effusion].

Authors:  B Maisch; A D Ristić
Journal:  Herz       Date:  2014-11       Impact factor: 1.443

4.  Cytopathology of pericardial effusions : Experience from a tertiary center of cardiology.

Authors:  C Gecmen; G G Gecmen; D Ece; M Kahyaoğlu; A Kalayci; C Y Karabay; O Candan; M E Isik; F Yilmaz; O Akgun; M Celik; I A Izgi; C Kirma; S Keser
Journal:  Herz       Date:  2017-07-10       Impact factor: 1.443

5.  [Management of pericarditis and pericardial effusion, constrictive and effusive-constrictive pericarditis].

Authors:  B Maisch
Journal:  Herz       Date:  2018-11       Impact factor: 1.443

6.  Postpericardiotomy syndrome after cardiac surgery.

Authors:  Joonas Lehto; Tuomas Kiviniemi
Journal:  Ann Med       Date:  2020-05-02       Impact factor: 4.709

Review 7.  Pericardial Disease Associated with Malignancy.

Authors:  Ryan Schusler; Shari L Meyerson
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

8.  Echo-guided pericardiocentesis in patients with clinically significant pericardial effusion. Outcomes over a 10-year period.

Authors:  S Akyuz; A Zengin; E Arugaslan; S Yazici; T Onuk; U S Ceylan; B Gungor; U Gurkan; T Kemaloglu Oz; H Kasikcioglu; N Cam
Journal:  Herz       Date:  2014-12-11       Impact factor: 1.443

9.  Causes and prognosis of symptomatic pericardial effusions treated by pericardiocentesis in an Asian academic medical centre.

Authors:  Xian Pei Cheong; Lawrence Ka Peng Law; Swee-Chong Seow; Lik Wui Edgar Tay; Huay Cheem Tan; Wee Tiong Yeo; Adrian F Low; Pipin Kojodjojo
Journal:  Singapore Med J       Date:  2019-07-11       Impact factor: 1.858

10.  Hemoglobin-associated oxidative stress in the pericardial compartment of postoperative cardiac surgery patients.

Authors:  Philip A Kramer; Balu K Chacko; Saranya Ravi; Michelle S Johnson; Tanecia Mitchell; Stephen Barnes; Alireza Arabshahi; Louis J Dell'Italia; David J George; Chad Steele; James F George; Victor M Darley-Usmar; Spencer J Melby
Journal:  Lab Invest       Date:  2014-12-01       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.